OPHLF (Ono Pharmaceutical Co) Cyclically Adjusted Revenue per Share: $4.74 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OPHLF Ono Pharmaceutical Co Ltd OPHLF
75 GF Score
Price $14.45
GF Value $12.86
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ono Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Ono Pharmaceutical Co OPHLF +0.36% 75 Cyclically Adjusted Revenue per Share is $4.74 as of Mar. 2026. GuruFocus rates OPHLF with a GF Score™ of 75/100 and a GF Value™ of $12.86 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ono Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was $1.593. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.74 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ono Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ono Pharmaceutical Co was 16.30% per year. The lowest was 9.60% per year. And the median was 13.50% per year.

As of today (2026-07-18), Ono Pharmaceutical Co's current stock price is $14.45. Ono Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $4.74. Ono Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 3.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ono Pharmaceutical Co was 10.51. The lowest was 2.05. And the median was 5.97.


Ono Pharmaceutical Co  (OTCPK:OPHLF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ono Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=14.45/4.74
=3.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ono Pharmaceutical Co was 10.51. The lowest was 2.05. And the median was 5.97.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ono Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Ono Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ono Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ono Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Ono Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.94 4.13 4.31 5.11 4.74

Ono Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.11 4.52 4.73 4.77 4.74

OPHLF vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ono Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


OPHLF
75GF Score
Ono Pharmaceutical Co Ltd OPHLF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ono Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ono Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.593/112.7000*112.7000
=1.593

Current CPI (Mar. 2026) = 112.7000.

Ono Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.052 98.100 1.209
201609 1.093 98.000 1.257
201612 1.157 98.400 1.325
201703 0.935 98.100 1.074
201706 1.041 98.500 1.191
201709 1.059 98.800 1.208
201712 1.363 99.400 1.545
201803 1.123 99.200 1.276
201806 1.259 99.200 1.430
201809 1.269 99.900 1.432
201812 1.366 99.700 1.544
201903 1.145 99.700 1.294
201906 1.335 99.800 1.508
201909 1.385 100.100 1.559
201912 1.401 100.500 1.571
202003 1.248 100.300 1.402
202006 1.395 99.900 1.574
202009 1.434 99.900 1.618
202012 1.630 99.300 1.850
202103 1.370 99.900 1.546
202106 1.589 99.500 1.800
202109 1.577 100.100 1.776
202112 1.718 100.100 1.934
202203 1.547 101.100 1.724
202206 1.631 101.800 1.806
202209 1.572 103.100 1.718
202212 1.857 104.100 2.010
202303 1.657 104.400 1.789
202306 1.739 105.200 1.863
202309 1.939 106.200 2.058
202312 1.915 106.800 2.021
202403 1.593 107.200 1.675
202406 1.586 108.200 1.652
202409 1.827 108.900 1.891
202412 1.857 110.700 1.891
202503 1.603 111.100 1.626
202506 1.877 111.700 1.894
202509 1.865 112.000 1.877
202512 1.909 113.000 1.904
202603 1.593 112.700 1.593

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.74 mean?
Ono Pharmaceutical Co (OPHLF) has a Cyclically Adjusted Revenue per Share of $4.74 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ono Pharmaceutical Co and its competitors.
Is Ono Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Ono Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $4.74. Overall, Ono Pharmaceutical Co has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Ono Pharmaceutical Co's Cyclically Adjusted Revenue per Share of $4.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ono Pharmaceutical Co and its competitors. Ono Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (OPHLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.86, compared to a current price of $14.45 — trading 12.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.74. Ono Pharmaceutical Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ono Pharmaceutical Co (OPHLF), the current Cyclically Adjusted Revenue per Share is $4.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ono Pharmaceutical Co (OPHLF) Overvalued in 2026?

Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued. The current stock price of $14.45 is trading 12.4% above its estimated GF Value™ of $12.86. GuruFocus considers Ono Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for OPHLF:

  • Cyclically Adjusted Revenue per Share: $4.74
  • GF Value™: $12.86 vs. price of $14.45 (12.4% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the OPHLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ono Pharmaceutical Co Business Description

Address 1-8-2 Kyutarocho, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
75GF Score

Get the complete analysis for OPHLF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.45
Price
$12.86
GF Value